Get the Stockscreener App
9.135
1.48%
0.125
Adma Biologics Inc stock is traded at $9.135, with a volume of 3.74M.
It is up +1.48% in the last 24 hours and down -41.27% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$9.01
Open:
$9.035
24h Volume:
3.74M
Relative Volume:
0.82
Market Cap:
$2.17B
Revenue:
$510.17M
Net Income/Loss:
$146.93M
P/E Ratio:
15.25
EPS:
0.599
Net Cash Flow:
$27.51M
1W Performance:
-5.05%
1M Performance:
-41.27%
6M Performance:
-39.25%
1Y Performance:
-52.92%
1-Day Range:
$8.99
$9.60
1-Week Range:
$7.2101
$9.805
52-Week Range:
$7.2101
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.13 | 2.15B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
448.21 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
773.08 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
749.95 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.61 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
165.20 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA Investor Alert: ADMA Biologics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Revenue Headwinds: Levi & Korsinsky - Morningstar
ADMA Biologics Under Investigation for Securities Fraud - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Investors to Reach Out - ACCESS Newswire
Investor Notice: ADMA Biologics ($ADMA) Stock Dropped 29% After Culper Research Report AnnouncementInvestigation Pending - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA ... - Bluefield Daily Telegraph
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential ... - Bluefield Daily Telegraph
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact - GlobeNewswire
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
ADMA Biologics Investigated for Securities Fraud After Stock Drop - National Today
ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop - PR Newswire
Adma Biologics (ADMA) Shares Fall as Overall Market Rises: Key Insights for Investors - Bitget
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Reach Out - ACCESS Newswire
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating - PR Newswire
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
2026-03-30 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Reach Out | NDAQ:ADMA | Press Release - Stockhouse
$ADMA Investor News: ADMA Biologics Faces Securities Fraud - GlobeNewswire
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA’s Upward Candlesticks Face Off Against a 41.6% Price Decline — What Lies Ahead? - Bitget
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Connect - ACCESS Newswire
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Connect | NDAQ:ADMA | Press Release - Stockhouse
Did ADMA Biologics($ADMA) Mislead Investors about Channel Stuffing Issues? Investors with Losses Notified of Ongoing Securities Fraud Investigation - ACCESS Newswire
ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade) - Seeking Alpha
ADMA Biologics Inc (NASDAQ:ADMA) Short Interest Update - MarketBeat
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
Does ADMA Biologics’ (ADMA) Rebuttal to Short-Seller Claims Strengthen Its Management Credibility Narrative? - Yahoo Finance
ADMA Biologics (ADMA) soars 11.6% as firm denies short seller allegations - msn.com
ADMA stock drops 6% after Culper Research alleges channel stuffing - msn.com
ADMA Biologics extends selloff as Cantor downgrades after short report - msn.com
Is ADMA Biologics' (ADMA) Rebuttal of Short-Seller Claims a Crucial Test of Management Credibility? - Sahm
5 Stocks Investors Are Tracking Now - Insider Monkey
ADMA Biologics (ADMA) Soars 11.6% as Firm Denies Short Seller Allegations - Yahoo Finance
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - The National Law Review
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over - GlobeNewswire
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating - GlobeNewswire Inc.
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research - StreetInsider
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
ADMA Biologics (NASDAQ:ADMA) Shares Gap UpHere's Why - MarketBeat
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. ... - Bluefield Daily Telegraph
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report? - Yahoo Finance
ADMA Biologics’ Shares React To Market Movements Amidst Share Buyback Plans - StocksToTrade
2026-03-27 | ADMA Biologics, Inc. (ADMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:ADMA | Press Release - Stockhouse
ADMA Biologics (NASDAQ:ADMA) Addresses Market Attention As Nasdaq Today Reacts - Kalkine Media
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday - Benzinga
ADMA Jumps 15% in Late-Day Rally: Biotech Market Turbulence Escalates Amid Options Trading Momentum - Bitget
ADMA Biologics Defends Against Short Report Claims - Intellectia AI
ADMA Biologics gains after refuting short seller claims - Seeking Alpha
ADMA vs Culper: What’s Behind The 9% Pre-Market Spike Today? - Stocktwits
ADMA Biologics Issues Rebuttal to Short-Seller Allegations - TipRanks
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ADMA Biologics Inc recently responded to a short-selling report, firmly stating that the report presents a serious distortion and confusion regarding the actual efficacy and competitive position of its product Asceniv in the intravenous immunoglobulin (IVIG) mark - Bitget
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):